fda ends semaglutide shortage 🚨 The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant FDA: Ozempic and Wegovy drug

Many patients report that headaches diminish or resolve completely after the first month of therapy, suggesting an adaptation effect

Dont use the pen if the medication is discoloured, cloudy, frozen, or contains any particles Clean your hands thoroughly before injecting

Ozempic is a GLP1 receptor agonist that prompts your pancreas to release more insulin, decreases hepatic glucose production, slows digestion, and affects appetite centers in the brain

Because this is a small-molecule salt rather than a peptide, the usual peptide precautions about mechanical shear and methionine or tryptophan oxidation do not apply

For instance, a recently published study (Onwordi et al., 2021) showed that the correlation between the glutamate-to-creatine ratio measured by MRS and the [ 11 C]UCB-J distributed volume ratio is only significant in healthy volunteers (hippocampus and anterior cingulate cortex) and not in patients with schizophrenia

Several insurance companies, including Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare, typically cover Wegovy in some form or another